Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Optical Biosensors Are Increasingly Used at Point-of-Care and in Medical Laboratories

In clinical practices, optical biosensors are becoming more prevalent in point-of-care testing and in-house medical laboratories. One primary reason for their increased adoption is optical biosensors are non-invasive, alleviating the pain and inconvenience for patients when drawing blood. In addition, before this technology, many analyses had to be performed using large equipment located in central…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

In clinical practices, optical biosensors are becoming more prevalent in point-of-care testing and in-house medical laboratories. One primary reason for their increased adoption is optical biosensors are non-invasive, alleviating the pain and inconvenience for patients when drawing blood. In addition, before this technology, many analyses had to be performed using large equipment located in central laboratories, causing delays in diagnosis. Let’s take a look at the future of optical sensing at point-of-care and in medical laboratories.

Biosensors Are Used in a Wide Variety of Applications

Simply put, a biosensor is a self-contained analytical device combining a biological element with a physicochemical component to generate a measurable signal for further analysis. In recent years, biosensors have become more widely used in medical diagnostics and biotechnology, as well as in pharmaceuticals, food, beverage, environmental, and agricultural industries. This is due to their simplicity in operation, higher sensitivity, ability to perform multiplex analysis, and capability to be integrated with different functions by the same computer chip.

Biosensors are highly responsive, making them ideal for sensing real-time signals from the production of biomolecules. Blood glucose monitoring is one of the most popular applications of biosensors in recent years. Also, biosensors are used in clinical laboratories to detect lactate, peroxides, and cytokines, as well as the release of proteins or antibodies in different inflammatory diseases and tumors.

New Biosensor Technology Will Lead to Increased Adoption

Since the development of the first oxygen biosensor in 1962, there have been enormous strides in biosensor technology. Even so, the practical application of biosensors in the field of medicine is still in its infancy. Further growth will be driven by the creation of devices that are able to provide results at or near the patient efficiently.

In order to increase their adoption, these devices need further advancement regarding simplicity, sensitivity, multiplex analysis of multiple biomarkers, and integration of different functions by the same computer chip. This will allow non-laboratory personnel like nurses and respiratory therapists to perform testing directly at point-of-care. Additionally, in-house laboratories will gain the greater capability to perform more sophisticated testing that once had to outsourced to large industrial laboratories. This will result in more rapid turnaround times for test results, reduced costs, and higher patient satisfaction.

Fiberguide is Helping to Drive the Advancement of Biosensors

For biosensors to become more powerful and user-friendly, there must be continuous development in optical fiber technology. Fiberguide manufactures over 500 different specialty optical fibers packaged in a variety of assemblies and bundles for optical power delivery and optical sensing applications. Fiberguide has proved their commitment to reliable, long-term, strategic partnerships with OEM manufacturers, providing efficient, cost-effective, practical fiber optic solutions engineered to meet specific needs.

Read more at fiberguide.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512